Related Experiment Videos
[Pattern of antimicrobial susceptibility in uropathogen isolates from children]
V M Suárez1, R C Suárez, B A Pérez
1Sección de Nefrología Pediátrica, Hospital Central de Asturias, Oviedo. venancio@correo.uniovi.es
Summary
Escherichia coli is the most common cause of pediatric urinary tract infections. Cephalosporins and nitrofurantoin are recommended empirical treatments for children with bacteriuria.
Area of Science:
- Pediatric infectious diseases
- Bacteriology
- Antimicrobial resistance
Background:
- Urinary tract infections (UTIs) are common in children.
- Understanding the causative pathogens and their antibiotic susceptibility is crucial for effective treatment.
- Bacteriuria in children requires prompt diagnosis and management to prevent complications.
Purpose of the Study:
- To analyze the bacteriological profile of culture-positive bacteriuria in children over a 5-year period.
- To determine the most effective empirical antibiotic treatments for pediatric UTIs based on susceptibility data.
Main Methods:
- Retrospective analysis of children with culture-positive bacteriuria.
- Identification of bacterial pathogens and antimicrobial susceptibility testing.
- Evaluation of treatment outcomes based on susceptibility patterns.
Main Results:
- Escherichia coli was the predominant pathogen (57%), followed by Streptococcus faecalis (11%), Pseudomonas aeruginosa (8%), and Proteus mirabilis (6%).
- Antimicrobial susceptibility testing revealed cephalosporins (all generations) and nitrofurantoin as effective empirical oral treatments.
- Fosfomycin showed potential as an alternative treatment in select cases.
- For hospitalized children, empirical treatment with third-generation cephalosporins, potentially with gentamicin for severe cases, is advised.
Conclusions:
- The study highlights the prevalence of E. coli in pediatric UTIs.
- Cephalosporins and nitrofurantoin are recommended as first-line empirical therapies for childhood bacteriuria.
- Treatment guidelines should be informed by local antimicrobial susceptibility data for optimal patient outcomes.